Disease areas

Lung and respiratory diseases

24 public biotech companies we cover are developing treatments for pulmonary hypertension, pulmonary fibrosis, asthma, COPD and cystic fibrosis. 7 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

Drug pages

Seralutinib

Upcoming catalysts

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in Q4 2026

Expected in H2 2026

Expected by end of 2026

Expected in Q1 2027

Other disease areas